You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

12 Results
Guidelines and Advice
Status: Archived
ID: 22-2-1
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-2
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-3
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-4
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-5
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-6
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-7
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-8
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-9
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-10
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-M
Jun 2014
Regimen
Cancer Type:
Gynecologic, 
Cervix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
bevacizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2023